News | March 30, 2024
Aragen operationalizes first phase of its US$ 30 million Biologics manufacturing facility in India
Executes the first project for developing and manufacturing a novel anticancer mAb
Executes the first project for developing and manufacturing a novel anticancer mAb
Development services for gene and cell therapies is planned to begin first in 2025
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Increased capability to produce medicines for challenging diseases including cancer
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
The expansion makes Exothera one of the largest viral vector facilities in Europe
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
